Gary Simmons, DO, MSHA, discusses outpatient CAR T-cell therapy in the community, the operational and payer bottlenecks his practice has faced, and advice for colleagues.
|Videos|July 15, 2016
Next Steps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Author(s)Stanley Yap, MD
Stanley Yap, MD, assistant professor, urologic oncology, UC Davis Comprehensive Cancer Center, discusses needed improvements and next steps in neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Advertisement
Advertisement
Related to this article
FDA expands nogapendekin alfa inbakicept plus BCG use to high-grade papillary-only BCG-unresponsive NMIBC, offering durable control and strong cystectomy-avoidance outcomes.
Cancer deaths keep falling as survival rises, fueled by prevention, early detection, and therapies—yet gaps persist, and research funding uncertainty threatens future gains.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206
2
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
3
VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors
4
Durability of PFS and OS Benefit vs. Historical Control
5